Objective outcome measures: Collecting meaningful data on alopecia areata - 16/08/18
Doi : 10.1016/j.jaad.2017.10.048
Elise A. Olsen, MD a, ⁎ 
, Janet Roberts, MD b, Leonard Sperling, MD c, Antonella Tosti, MD d, Jerry Shapiro, MD e, Amy McMichael, MD f, Wilma Bergfeld, MD g, Valerie Callender, MD h, Paradi Mirmirani, MD i, Ken Washenik, MD, PhD e, j, David Whiting, MD k, George Cotsarelis, MD l, Maria Hordinsky, MD m
, Janet Roberts, MD b, Leonard Sperling, MD c, Antonella Tosti, MD d, Jerry Shapiro, MD e, Amy McMichael, MD f, Wilma Bergfeld, MD g, Valerie Callender, MD h, Paradi Mirmirani, MD i, Ken Washenik, MD, PhD e, j, David Whiting, MD k, George Cotsarelis, MD l, Maria Hordinsky, MD m a Duke University Medical Center, Durham, North Carolina
b Northwest Dermatology and Research Center, Portland, Oregon
c HCT Pathology Services, Baltimore, Maryland
d University of Miami, Miami, Florida
e New York University, New York, New York
f Wake Forest Baptist Health Medical Center, Winston-Salem, North Carolina
g Cleveland Clinic, Cleveland, Ohio
h Howard University College of Medicine, Washington, DC
i The Permanente Medical Group, Vallejo, California
j Bosley Medical Group, Beverly Hills, California
k Baylor Hair Research Center, Dallas, Texas
l University of Pennsylvania, Philadelphia, Pennsylvania
m University of Minnesota, Minneapolis, Minnesota
∗Correspondence to: Elise A. Olsen, MD, Box 3294, Duke University Medical Center, Durham, NC 27710.Box 3294, Duke University Medical CenterDurhamNC27710
Abstract |
Background |
Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking.
Objective |
To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata.
Methods |
Literature review and expert opinion of a group of dermatologists specializing in hair disorders.
Results |
Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented.
Limitations |
The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice.
Conclusion |
Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.
Le texte complet de cet article est disponible en PDF.Key words : ALODEX score, alopecia areata, assessment measures, outcome measures, response criteria, SALT score
Abbreviations used : AA, ALODEX, BL, LAD, S, SALT
Plan
| Supported in part by the Duke University Hair Disorders Research and Treatment Center and the Leirion Foundation. |
|
| Disclosure: Dr Olsen reports serving as a consultant for Incyte, Concert, Kerastem, Lilly, and Cassiopeia; serving as a consultant for and having another relationship with Allergan; serving on advisory boards for Aclaris and Samumed; and having another relationship with UpToDate. Dr Roberts reports serving as an investigator for Incyte, Concert, Allergan, Samumed, and Theradome. Dr Tosti reports serving on an advisory board and as an investigator for Incyte; serving on advisory boards for Kythera and Aclaris; serving as a consultant for P&G, DS Laboratories, and Polichem; and having other relationships with Karger, Taylor & Francis, and Springer Verlag. Dr Shapiro reports serving as a consultant for Biologics, J&J, Incyte, and Merck; serving as a consultant for and being a stockholder of Eirion; being a stockholder of and creating intellectual property with Replicel Life Sciences, Inc; serving on advisory boards for Applied Biology, Aclaris, and Samumed; and serving as an investigator for Allergan and Regenlab. Dr McMichael reports serving as a consultant for Aclaris, J&J, Covance, eResearch Technology, Guthey Renker, Intraderm, Merck and Co, and Pfizer; being an investigator and advisory board member for Allergan; serving as a consultant and investigator for Galderma, P&G, Samumed, and Incyte; creating intellectual property with Informa Healthcare; serving as an investigator for Cassiopea; and having another relationship with UpToDate. Dr Mirmirani reports serving as a consultant for Cassiopeia and Samumed, being an investigator for Concert, and having another relationship with UpToDate. Dr Bergfeld reports serving as a consultant for Concert, Cassiopeia, Aclaris, P&G, and Pfizer; serving as a consultant and investigator for Allergan; serving as an advisory board member for J&J, Samumed, Kythera, and Incyte; and having another relationship with UpToDate. Dr Callender reports serving as a consultant and investigator for Aclaris, Allergan, Avon, and Gallderma; serving as a consultant for Cassiopeia, Intraderm, L'Oreal, Pfizer, Promius, Samumed, Sensus Healthcare, and Unilever; serving as an investigator for Nevance; and having another relationship with UpToDate. Dr Washenik reports serving as a consultant for Cassiopeia, Aclaris, Allergan, and J&J; serving on an advisory board for Follica and Kythera; serving as a consultant and investigator for Kerastem; serving as a medical monitor for Theradome; being a stockholder of Bosley Medical Group; and creating intellectual property with Aderans. Dr Cotsarelis reports serving as a consultant for Cassiopeia and Lilly, serving as a consultant for J&J, serving as an investigator for Allergan, creating intellectual property with the University of Pennsylvania, and serving as an advisory board member for Follica. Dr Hordinsky reports serving as a consultant for Biologics Inc, P&G, and Pfizer; serving as a consultant and investigator for Concert; serving as an investigator for Allergan; serving as an advisory board member and investigator for Incyte; serving as an advisory board member for Aclaris; and having other relationships with Informa Healthcare, McGraw-Hill, and UpToDate. Drs Sperling and Whiting have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc. Tous droits réservés.
Vol 79 - N° 3
P. 470 - septembre 2018 Retour au numéro
Article précédent
- Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index
- Peter B. Chansky, Jeannette M. Olazagasti, Rui Feng, Victoria P. Werth
- A split-face, single-blinded, randomized controlled comparison of alexandrite 755-nm picosecond laser versus alexandrite 755-nm nanosecond laser in the treatment of acquired bilateral nevus of Ota–like macules
- Wenyou Yu, Jiafang Zhu, Wenxin Yu, Dongze Lyu, Xiaoxi Lin, Zhen Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?